Printer Friendly

Sanko Junyaku, Eisai and Fujirebio Sign Joint Research Agreement for Development of New KL-6 Test Kit.

Tokyo, Japan, Oct 19, 2006 - (JCN) - Sanko Junyaku Co., Ltd., Eisai Co., Ltd. and Fujirebio Inc. today announced their conclusion of a joint research agreement for development of a new KL-6 test kit consisting of an in-vitro, supplementary diagnostic marker for interstitial pneumonia compatible with LUMIPULSE (automatic chemiluminescent enzyme immunoassay) systems.

Sanko Junyaku currently manufactures and markets two test kits for interstitial pneumonia, EITEST KL-6 (sandwich enzyme immunoassay method) and PICOLUMI KL-6 (electrochemiluminescence immunoassay) for measurement of KL-6, a serum marker that is highly distinctive for the diagnosis of the disease, under a sales agreement with Eisai. With this new agreement, the three companies aim to develop a new KL-6 test kit compatible with diagnosis by LUMIPULSE systems, allowing for greater ease of use in diagnosis of interstitial pneumonia.

Fujirebio markets three automatic chemiluminescent enzyme immunoassay systems, LUMIPULSEf, LUMIPULSE S and LUMIPULSE Presto II. Today, more than 1000 LUMIPULSE systems have been used in medical institutions throughout Japan. The development of a new KL-6 test kit will further extend the measurement items of the LUMIPULSE systems, giving them the higher diagnostic capability.

Under today's agreement, the new KL-6 test kit will be manufactured by Fujirebio, while Sanko Junyaku and Eisai will be responsible for marketing and sales of the products.

Typical types of interstitial pneumonia include cryptogenic interstitial pneumonia and drug-induced pneumonia, both of which are designated as intractable disorders. Furthermore, cases of drug-induced pneumonia have been increasing recently, raising the significance of and public concern about this disease. Sanko Junyaku, Eisai and Fujirebio are committed to increasing benefits to patients and their families through the development of the new test kit.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 19, 2006
Words:282
Previous Article:Siam United Steel Becomes Consolidated Subsidiary of Nippon Steel.
Next Article:Sanko Lifetech Transfers Animal Health Products Business to Novartis Animal Health.
Topics:


Related Articles
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Sanko Junyaku Patents Its Proprietary Gene Amplification Method PALSAR in EU.
Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters